Population pharmacokinetic/pharmacodynamic joint modeling of ixazomib efficacy and safety using data from the pivotal phase III TOURMALINE‐MM1 study in multiple myeloma patients

Ixazomib is an oral proteasome inhibitor approved in combination with lenalidomide and dexamethasone for the treatment of relapsed/refractory multiple myeloma (MM). Approval in the United States, Europe, and additional countries was based on results from the phase III TOURMALINE‐MM1 (C16010) study....

Descripción completa

Detalles Bibliográficos
Autores principales: Srimani, Jaydeep K., Diderichsen, Paul M., Hanley, Michael J., Venkatakrishnan, Karthik, Labotka, Richard, Gupta, Neeraj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381907/
https://www.ncbi.nlm.nih.gov/pubmed/35598166
http://dx.doi.org/10.1002/psp4.12815

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381907/
https://www.ncbi.nlm.nih.gov/pubmed/35598166
http://dx.doi.org/10.1002/psp4.12815

Ejemplares similares